SEARCH

SEARCH BY CITATION

References

  • 1
    Idilman R, de Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepatitis 1997; 4: 8191.
  • 2
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 18991905.
  • 3
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 4
    Seeff LB, Buskel-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger B, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 19061911.
  • 5
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 10511055.
  • 6
    Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type C. J Hepatol 1997; 27: 201205.
  • 7
    Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, et al. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141147.
  • 8
    Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau J-M Le groupe Français pour l'etude du traitement des Hépatites chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686690.
  • 9
    Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993; 17 (suppl 3): 123126.
  • 10
    Brouwer JT, Nevens F, Kleter BEM, Elewaut A, Adler M, Brenard R, Chamuleau RAFM, et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients [Abstract]. J Hepatol 1995; 23 (suppl 1): 84.
  • 11
    Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavaletto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: a meta-analysis of individual patient data from European patients. J Hepatol 1997; 26: 961966.
  • 12
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underbill JA, Donaldson PT, Maertens G, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 13
    Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Urdea M, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 11371143.